Fig. 1 · Structure

Documents & Downloads

Duvelisib (IPI-145, INK1197)

Cat. No. A12422 CAS 1201438-56-3

PI3K-δ/PI3K-γ inhibitor

IPI-145, also known as INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PI3Kδ ki 23pM
PI3Kγ ki 243pM
PI3Kδ ki 23pM
PI3Kβ ki 1564pM
PI3Kα ki 25900pM
PI3Kγ ki 243pM

6 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
4T1 IC50 22.88 μM Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 37011446]
A549 IC50 > 100 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 37011446]
B16-F10 IC50 > 100 μM Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 37011446]
DOHH-2 IC50 0.2 μM Antiproliferative activity against human DOHH-2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay [PMID: 35831917]
HepG2 IC50 > 100 μM Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 37011446]
Huh-7 IC50 6.57 μM Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 37011446]
Jurkat IC50 1.9 μM Antiproliferative activity against human Jurkat cells after 3 days by CellTiter-Glo assay [PMID: 27774127]
Jurkat IC50 3.17 μM Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 37011446]
L929 IC50 > 100 μM Cytotoxicity against mouse L929 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 37011446]
LOUCY IC50 0.98 μM Antiproliferative activity against human Loucy cells after 3 days by CellTiter-Glo assay [PMID: 27774127]
MCF7 IC50 > 100 μM Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 37011446]
MDA-MB-231 IC50 9.76 μM Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 37011446]
MOLM-14 IC50 1.2 μM Antiproliferative activity against human MOLM14 cells after 3 days by CellTiter-Glo assay [PMID: 27774127]
MOLT-4 IC50 2.3 μM Antiproliferative activity against human MOLT4 cells after 3 days by CellTiter-Glo assay [PMID: 27774127]
MV4-11 IC50 4.4 μM Antiproliferative activity against human MV4-11 cells after 3 days by CellTiter-Glo assay [PMID: 27774127]
Ramos IC50 0.001 μM Inhibition of PI3Kdelta in human Ramos cells assessed as reduction in antihuman IgM-stimulated AKT phosphorylation at Ser473 residue preincubated for 60 mins followed by antihuman IgM stimulation and measured after 15 mins [PMID: 31033293]
RAW264.7 IC50 0.025 μM Inhibition of PI3Kgamma in rat RAW264.7 cells assessed as reduction in C5a-stimulated AKT phosphorylation at Ser473 residue preincubated for 30 mins followed by C5a-stimulation and measured after 5 mins [PMID: 31033293]
RAW264.7 IC50 13.2 μM Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay [PMID: 37011446]
Sf21 IC50 0.001 μM Inhibition of N-terminal His6-tagged recombinant full length human p110delta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 80 mins by transcreener fluorescence po [PMID: 31033293]

19 records · Scroll to view more

Duvelisib (IPI-145, INK1197) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Duvelisib (IPI-145, INK1197) from 4 published references. In vitro models include primary AML cells; DB cells. In vivo models include NSG mice.

Duvelisib (IPI-145, INK1197) In Vitro Studies

Duvelisib reduced primary AML blast survival with increasing concentrations, and AML samples were sensitive at 1000nM. In DB cells, Duvelisib substantially attenuated IKK and IκBα phosphorylation, with greater potency against IκBα. In Mlg cells without TGF‐β1 stimulation, Duvelisib showed a half-maximal inhibitory concentration of 12.94 μM at 24 h in the MTT cytotoxicity test. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Duvelisib effects on primary AML cells

Cell-based study · primary AML cells [1]

Primary AML cells showed reduced blast survival with increasing Duvelisib concentrations. AML samples were sensitive at 1000nM, with colonies visualised, measured and counted after 10 days.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of coloniesReported result Primary AML blast survival is reduced in response to increasing concentrations of IPI-145, after culture for 48 hours. AML samples were sensitive to the effects of IPI-145 at concentrations of 1000nM; colonies were visualised, measured and counted after 10 days.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1000nM
Exposure duration
after 10 days
Reported limits
Not stated in the sentences used: route, vehicle, control.
Methods and source locations

Compound reported in the paper: Duvelisib; Compound label in the paper: IPI 145

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > PI3K inhibition reduces the survival of AML blasts (S12, S14); MATERIALS AND METHODS > Methods > Clonogenic methylcellulose assays (S77); Figure 1 legend (S114)

number of colonies: number of colonies — RESULTS > PI3K inhibition reduces the survival of AML blasts (S12, S14); MATERIALS AND METHODS > Methods > Clonogenic methylcellulose assays (S77); Figure 1 legend (S114)

Attenuated IKK and IκBα Phosphorylation in DB Cells

Cell-based study · DB cells [2]

In DB cells, Duvelisib substantially attenuated phosphorylation of both IKK and IκBα, with greater potency against IκBα.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
protein expression levels of IKKα/β, p-IKKα/β (Ser176/180), IκBα and p-IκBα (Ser32)Reported result duvelisib substantially attenuated phosphorylation of both IKK and IκBα (with greater potency against IκBα)[2]

Literature-Reported Treatment Conditions

Vehicle
DMSO
Reported limits
Not stated in the sentences used: dose, route, schedule.
Methods and source locations

Compound reported in the paper: Duvelisib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Result > Duvelisib and chidamide stabilize IκBα in the cytoplasm through selective targeting of PI3K delta and HDAC2 (S55); Fig. 5 legend (S216, S220)

protein expression levels of IKKα/β, p-IKKα/β (Ser176/180), IκBα and p-IκBα (Ser32): protein expression levels of IKKα/β, p-IKKα/β (Ser176/180), IκBα and p-IκBα (Ser32); comparator: DMSO — Result > Duvelisib and chidamide stabilize IκBα in the cytoplasm through selective targeting of PI3K delta and HDAC2 (S55); Fig. 5 legend (S216)

Duvelisib cytotoxicity in Mlg cells

Cell-based study · Mlg cells [3]

Cytotoxicity test of Mlg cells (MTT), without TGF‐β1 stimulation. Mlg cells were exposed to the indicated doses of Duvelisib for 24 h, IC50 = 12.94 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cytotoxicity test of Mlg cells (MTT)IC50 without TGF‐β1 stimulation, 24 h: IC50 = 12.94 μM[3]

Literature-Reported Treatment Conditions

Exposure duration
24 h
Method
exposed
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Duvelisib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Duvelisib suppresses TGF‐β1‐induced proliferation of lung fibroblasts (S82, S83); FIGURE 2 legend (S135, S136, S143)

Cytotoxicity test of Mlg cells (MTT): Cytotoxicity test of Mlg cells (MTT); comparator: control group — RESULTS > Duvelisib suppresses TGF‐β1‐induced proliferation of lung fibroblasts (S82, S83); FIGURE 2 legend (S135, S136)

Duvelisib (IPI-145, INK1197) In Vivo Studies

NSG mice received Duvelisib by intraperitoneal injection. Duvelisib-treated animals had reduced tumour burden compared with vehicle control treated animals, as measured by bioluminescence. [4]

Reduced Tumour Burden in NSG Mice

Animal study · NSG mice [4]

In NSG mice, Duvelisib administered by intraperitoneal injection reduced tumour burden compared with vehicle control treated animals, as measured by bioluminescence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumour burdenReported result On day 18 after transplant (4 days after completion of the 10- day duvelisib treatment), duvelisib-treated animals had reduced tumour burden when compared to vehicle control treated animals, as measured by bioluminescence[4]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
daily for 10 days with duvelisib (15 mg/kg on days 5–14 following transplant)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Duvelisib 15 mg/kgvehicle control treated animalsOn day 18 after transplant (4 days after completion of the 10- day duvelisib treatment), duvelisib-treated animals had reduced tumour burden when compared to vehicle control treated animals, as measured by bioluminescence[4]
Duvelisib 15 mg/kg
Model: NSG mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Duvelisib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > MM xenograft model (S40, S43, S44); Results > PI3Kδ/γ inhibition significantly reduces engraftment and tumour burden in vivo (S102, S103, S104)

tumour burden: tumour burden; comparator: vehicle control treated animals — Results > PI3Kδ/γ inhibition significantly reduces engraftment and tumour burden in vivo (S104)

Duvelisib 15 mg/kg · Materials and methods > MM xenograft model (S44); Results > PI3Kδ/γ inhibition significantly reduces engraftment and tumour burden in vivo (S103, S104)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1201438-56-3
Applications PI3K-δ/PI3K-γ inhibitor
Formula C22H17ClN6O
Molecular Weight 416.86
Synonyms IPI145; IPI-145. INK-1197; INK 1197
SMILES
C[C@@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 76 mg/mL (182.31 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Duvelisib (IPI-145, INK1197) Research References

  1. [1] Pillinger G, Loughran NV, Piddock RE, et al. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget (2016). PMID: 27174919 DOI: 10.18632/oncotarget.9289 Source material
  2. [2] Yao J, Li M, Jiang Y, et al. Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma. Cell Death Discov (2025). PMID: 41053160 DOI: 10.1038/s41420-025-02756-7 Source material
  3. [3] Li X, Ma X, Miao Y, et al. Duvelisib attenuates bleomycin-induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway. J Cell Mol Med (2023). PMID: 36651446 DOI: 10.1111/jcmm.17665 Source material
  4. [4] Piddock RE, Loughran N, Marlein CR, et al. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment. Blood Cancer J (2017). PMID: 28282033 DOI: 10.1038/bcj.2017.16 Source material

Added to your cart

View Cart Checkout
Loading...